Outcome in 203 patients (PTS) with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) with salvage therapy (RX): Retreatment with fludarabine (FLU).

被引：0
|
作者：
Thomas, D [1 ]
O'Brien, S [1 ]
Kantarjian, H [1 ]
Giles, FJ [1 ]
Lerner, S [1 ]
Keating, MJ [1 ]
机构：
[1] Univ Texas, Md Anderson Canc Ctr, Leukemia Sect, Houston, TX USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
419
引用
收藏
页码：102A / 103A
页数：2
相关论文
共 50 条
  • [1] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Ricci, Francesca
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Morra, Enrica
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 41 - 52
  • [2] Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Elter, Thomas
    Kilp, Julia
    Borchmann, Peter
    Schulz, Holger
    Hallek, Michael
    Engert, Andreas
    Haematologica-The Hematology Journal, 2009, 94 (01): : 150 - 152
  • [3] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
    Montillo, Marco
    Tedeschi, Alessandra
    Ricci, Francesca
    Zaccaria, Alfonso
    Crugnola, Monica
    Spriano, Mauro
    Spedini, PierAngelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    De Blasio, Angelo
    Vismara, Eleonora
    Morra, Enrica
    Petrizzi, Valeria Belsito
    BLOOD, 2010, 116 (21) : 595 - 596
  • [4] RITUXIMAB PLUS BENDAMUSTINE IN ELDERLY PATIENTS AFFECTED BY RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Lucania, A.
    Villa, M. R.
    Izzo, G. Nitrato
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [5] Outpatient-based therapy with oral fludarabine and alemtuzumab for Asian patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
    Hwang, William
    Dearden, C.
    Loh, S. M.
    Linn, Y. C.
    Tien, S. L.
    Teoh, G.
    Lim, L. F.
    Liew, P. X.
    How, G. F.
    Heng, K. K.
    Goh, Y. T.
    Lee, L. H.
    BLOOD, 2006, 108 (11) : 336B - 337B
  • [6] Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
    Kittai, Adam S.
    Best, Scott
    Thurlow, Bria
    Lam, Vi
    Hashiguchi, Taylor
    Goodyear, Shaun
    Persky, Daniel O.
    Okada, Craig
    Park, Byung
    Spurgeon, Stephen E.
    Danilov, Alexey V.
    HAEMATOLOGICA, 2021, 106 (07) : 2022 - 2025
  • [7] Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia
    Gjedde, SB
    Hansen, MM
    LEUKEMIA & LYMPHOMA, 1996, 21 (3-4) : 317 - 320
  • [8] An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
    Montillo, Marco
    Tedeschi, Alessandra
    Petrizzi, Valeria Belsito
    Ricci, Francesca
    Crugnola, Monica
    Spriano, Mauro
    Spedini, Pierangelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    Vismara, Eleonora
    De Blasio, Angelo
    Zaccaria, Alfonso
    Morra, Enrica
    BLOOD, 2011, 118 (15) : 4079 - 4085
  • [9] Activity of fludarabine in patients (PTS) with de novo B-cell prolymphocytic leukemia (PLL) and the prolymphocytoid variant of chronic lymphocytic leukemia (CLL-PRO).
    Rodríguez, J
    O'Brien, S
    Lerner, S
    Cortés, J
    Kantarjian, H
    Keating, M
    BLOOD, 1998, 92 (10) : 104A - 104A
  • [10] Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy
    Marotta, G
    Bigazzi, C
    Lenoci, M
    Tozzi, M
    Bocchia, M
    Lauria, F
    HAEMATOLOGICA, 2000, 85 (12) : 1268 - 1270
12345